Physician profile
Gregory Busse
NPI 1740257328
$5,254.84
in general payments reported to CMS, 2019-2025
45 companies · $1,016 in 2025
The $1,016 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,320 · 2020: $260 · 2021: $354 · 2022: $533 · 2023: $885 · 2024: $887 · 2025: $1,016.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,787.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $648.56 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $557.05 | 2019-2025 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $433.94 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $413.05 | 2019-2025 | Linzess, Viberzi, Ubrelvy |
| Pfizer INC. | $350.64 | 2019-2025 | |
| Glaxosmithkline, LLC. | $332.89 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $250.12 | 2019-2024 | Xarelto, Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.82 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $194.70 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.14 | 2019-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $132.12 | 2022-2025 | Freestyle Libre 3, Eterna |
| E.R. Squibb & Sons, L.L.C. | $126.93 | 2022-2024 | Eliquis |
| Merck Sharp & Dohme LLC | $107.45 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Novartis Pharmaceuticals Corporation | $103.49 | 2019-2024 | |
| Amneal Pharmaceuticals LLC | $99.77 | 2019-2023 | Unithroid |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Busse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.